Allan Rubenstein - Cooper Companies, Chairman
| COO Stock | USD 101.88 0.12 0.12% |
Chairman
Dr. Allan E. Rubenstein, M.D., is Independent Vice Chairman of the Board, Lead Director of Cooper Companies Inc. Dr. Rubenstein has served as our Vice Chairman and Lead Director since July 2002, and previously served as Chairman of the Board from July 1994 through July 2002. He served as Acting Chairman of the Board from April 1993 through June 1994. He is also Clinical Professor of Neurology and Pediatrics at New York University Langone Medical Center. Formerly, he was Chief Executive Officer of NexGenix Pharmaceuticals in NYC from 2003 to 2011. He currently serves as chairman of the scientific advisory board for Plex Pharmaceuticals since September 2017. He is also a trustee of the Connecticut River Museum in Essex, Connecticut. Previously, he served as a director of BioClinica, a specialty clinical trials company, from 2000 to 2003. He is also Medical Director Emeritus of the Childrens Tumor Foundation and a consultant to the National Institutes of Health, the U.S. Food and Drug Administration and the U.S. Department of Defense, where he served as Chair of the Army Neurofibromatosis Research Program Integration Panel in 2001. since 2002.
| Age | 74 |
| Tenure | 22 years |
| Professional Marks | Ph.D |
| Address | 6101 Bollinger Canyon Road, San Ramon, CA, United States, 94583 |
| Phone | 925 460 3600 |
| Web | https://www.coopercos.com |
Cooper Companies, Management Efficiency
The company has Return on Asset of 0.0339 % which means that on every $100 spent on assets, it made $0.0339 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0465 %, implying that it generated $0.0465 on every 100 dollars invested. Cooper Companies,'s management efficiency ratios could be used to measure how well Cooper Companies, manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of November 2024, Return On Tangible Assets is likely to grow to 0.06. Also, Return On Capital Employed is likely to grow to 0.05. At this time, Cooper Companies,'s Other Assets are very stable compared to the past year. As of the 13th of November 2024, Net Tangible Assets is likely to grow to about 2.7 B, while Intangibles To Total Assets are likely to drop 0.32.Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Vivek Jain | ICU Medical | 52 | |
| Patrick Zenner | West Pharmaceutical Services | 73 | |
| Ellen Zane | Haemonetics | 69 | |
| Ronald Gelbman | Haemonetics | 70 | |
| Richard Meelia | Haemonetics | 71 | |
| Stephen MacMillan | Hologic | 60 | |
| George Fotiades | AptarGroup | 67 | |
| Peter Farrell | ResMed Inc | 78 | |
Management Performance
| Return On Equity | 0.0465 | ||||
| Return On Asset | 0.0339 |
Cooper Companies, Leadership Team
Elected by the shareholders, the Cooper Companies,'s board of directors comprises two types of representatives: Cooper Companies, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cooper. The board's role is to monitor Cooper Companies,'s management team and ensure that shareholders' interests are well served. Cooper Companies,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cooper Companies,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allan Rubenstein, Independent Vice Chairman of the Board, Lead Director | ||
| William Kozy, Lead Independent Director | ||
| Robert Weiss, CEO and President Non-Independent Director and Member of Science and Technology Committee | ||
| Teresa Madden, Independent Director | ||
| Holly Sheffield, Executive Vice President and Chief Strategy Officer | ||
| Kim Duncan, Senior Director - Investor Relations | ||
| Agostino Ricupati, Senior Vice President - Finance and Tax, Chief Accounting Officer | ||
| Mark Drury, Vice President General Counsel, Secretary | ||
| Randal Golden, Vice President, General Counsel, Secretary | ||
| Gerard III, I CooperVision | ||
| Robert Auerbach, President - CooperSurgical | ||
| A Bender, Independent Chairman of the Board | ||
| Warner H, President CooperVision, Inc | ||
| Gary Petersmeyer, Independent Director | ||
| Daniel McBride, Chief Operating Officer, Executive Vice President, President of CooperVision, Inc. | ||
| Maria Rivas, Independent Director | ||
| Daniel Esq, Executive COO | ||
| Jody Lindell, Independent Director | ||
| Colleen Jay, Independent Director | ||
| Nicholas Khadder, General Secretary | ||
| Albert White, President, Chief Executive Officer, Director | ||
| Juan Aragon, Pres Division | ||
| Brian Andrews, Chief Financial Officer, Executive Vice President, Treasurer | ||
| Albert III, CEO President |
Cooper Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cooper Companies, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0465 | ||||
| Return On Asset | 0.0339 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 23.11 B | ||||
| Shares Outstanding | 199.16 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 99.41 % | ||||
| Number Of Shares Shorted | 2.24 M | ||||
| Price To Earning | 35.89 X |
Pair Trading with Cooper Companies,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cooper Companies, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cooper Companies, will appreciate offsetting losses from the drop in the long position's value.Moving against Cooper Stock
| 0.73 | MASS | 908 Devices | PairCorr |
| 0.66 | GH | Guardant Health Buyout Trend | PairCorr |
| 0.58 | AGL | agilon health | PairCorr |
| 0.54 | MBOT | Microbot Medical | PairCorr |
| 0.53 | DXCM | DexCom Inc | PairCorr |
The ability to find closely correlated positions to Cooper Companies, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cooper Companies, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cooper Companies, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling The Cooper Companies, to buy it.
The correlation of Cooper Companies, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cooper Companies, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cooper Companies, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cooper Companies, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in The Cooper Companies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cooper Companies,. If investors know Cooper will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cooper Companies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.209 | Earnings Share 1.8 | Revenue Per Share 19.14 | Quarterly Revenue Growth 0.078 | Return On Assets 0.0339 |
The market value of Cooper Companies, is measured differently than its book value, which is the value of Cooper that is recorded on the company's balance sheet. Investors also form their own opinion of Cooper Companies,'s value that differs from its market value or its book value, called intrinsic value, which is Cooper Companies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cooper Companies,'s market value can be influenced by many factors that don't directly affect Cooper Companies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cooper Companies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cooper Companies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cooper Companies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.